Raymond James bullish on biotech firms on favorable valuation

June 12, 2025 12:03 AM AEST | By Investing

Google News:

Raymond James bullish on biotech firms on favorable valuation — Image source: Kalkine Media

Recent News

Igloo Launches ‘The Cooler Brand’ Campaign Inspiring Enjoyment for All

Lawmakers push to ban direct-to-consumer drug advertising, WSJ reports

Single passenger survives Air India crash; Boeing and GE shares slide

Chime IPO surges 59% in NASDAQ debut

Investing.com -- Raymond James started coverage on biotechnology companies, rating Avidity Biosciences and Disc Medicine at Strong Buy and assigning Outperform ratings to Dyne Therapeutics, Tectonic Therapeutic, and Wave Life Sciences (NASDAQ:WVE), pointing to a sector-wide opportunity amid “suppressed valuations.”

Recent market weakness has created an attractive setup for investors willing to take on risk in high potential clinical-stage names, with upcoming catalysts likely to re-rate shares across several of its covered companies.

Raymond (NSE:RYMD) James initiated Avidity Biosciences at Strong Buy with a $65 price target, calling its AOC (antibody oligonucleotide conjugate) platform “ready for prime time.”

The firm sees high conviction in Avidity’s lead candidate del-zota for Duchenne muscular dystrophy and highlighted significant upside from potential first-mover drugs targeting DM1 and FSHD, both of which have large market opportunities.

Disc Medicine was also rated Strong Buy, with an $89 target.

Raymond James expects upside from bitopertin, its lead program in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and said the broader pipeline provides “two free call options.”

For Dyne Therapeutics, the firm assigned an Outperform rating with a $37 target, arguing that the market is undervaluing DYNE-101, its DM1 program.

It believes regulatory clarity could lift sentiment.

Tectonic Therapeutic, rated Outperform with a $76 price target, was described as having one of the most attractive risk/reward profiles in the firm’s coverage.

Its TX45 asset is being tested in pulmonary hypertension and has shown early clinical activity.

Wave Life Sciences was rated Outperform with a $14 target, with Raymond James citing favorable risk/reward into key Phase 2 data updates in obesity and alpha-1 antitrypsin deficiency in the second half of 2025.

This article first appeared in Investing.com

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.